Back to search
Indolent or Intermediate Grade B-cell Malignancy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Indolent or Intermediate Grade B-cell Malignancy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Indolent or Intermediate Grade B-cell Malignancy trials you may qualify forThis phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma. I…
The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or…
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monocl…